Executive Summary
The WHO Global Status Report on Cancer 2026 represents the most authoritative assessment of worldwide cancer burden, implementation progress, and policy gaps ever published. Released by the World Health Organization in collaboration with the International Agency for Research on Cancer (IARC), this landmark report synthesizes population-based cancer registries, epidemiological surveillance data, and — for the first time — a global lived-experience survey of over 4,000 individuals across 116 countries.
Key findings at a glance:
- 20.6 million new cancer cases diagnosed worldwide in 2024; 9.7 million deaths
- 35 million new cases projected annually by 2050 — a 66.7% increase from 2024
- 1 in 5 people will develop cancer in their lifetime (cumulative risk, 0–74 years: 19.8%)
- 92% of all people globally are affected by cancer at some point — personally or as a caregiver
- Only 12 countries are on track to meet the SDG 3.4 target (one-third reduction in premature cancer mortality by 2030)
- 48 countries have rising rates of premature cancer mortality
- Nearly 40% of new cancer cases are preventable through modifiable risk factor reduction
- The cumulative economic cost of cancer, 2020–2050: US$ 33.2 trillion — equivalent to an annual global GDP tax of 0.55%
- Every US$ 1 invested in cancer prevention and control yields a social return of US$ 9.50
1. About the Report & Methodology
Full title: Global Status Report on Cancer 2026: The Future We Choose Together
Publisher: World Health Organization (WHO), Geneva Co-publishing partner: International Agency for Research on Cancer (IARC) Publication year: 2026 ISBN (electronic): 978-92-4-012397-7 ISBN (print): 978-92-4-012398-4 Licence: CC BY-NC-SA 3.0 IGO Report length: 282 pages
Report structure:
| Section | Title | Pages |
|---|---|---|
| 1 | Introduction | 1–6 |
| 2 | The Global Cancer Burden: Data & Lived Experience | 7–56 |
| 3 | Status Update: Progress & Implementation Gaps | 57–134 |
| 4 | Drivers of Success & Systemic Challenges | 135–204 |
| 5 | A Future We Choose Together | 205–224 |
| Annex + References | Supporting Materials | 225–282 |
Data sources:
- GLOBOCAN 2024 (IARC)
- WHO Global Health Estimates 2021
- WHO CONCORD program (cancer survival)
- WHO Global Cancer Monitoring Framework (GCMF) indicators
- National Cancer Control Plan (NCCP) surveys
- National population-based cancer registries (PBCR)
- WHO global survey on lived experience of people affected by cancer (N=4,262 respondents, 116 countries)
Funding acknowledgments: City Cancer Challenge, European Society of Medical Oncology, Republic of Korea, St. Jude Children’s Research Hospital, WHO Foundation
2. The Global Cancer Burden — 2024 Incidence & Mortality
2.1 New Cancer Cases (Incidence) in 2024
In 2024, an estimated 20.6 million people worldwide received a new cancer diagnosis (including non-melanoma skin cancer). Excluding non-melanoma skin cancer, there were 19.5 million new cases: 9.9 million in men and 9.6 million in women.
Cumulative risk (0–74 years): Approximately 19.8% — meaning roughly 1 in 5 people will develop cancer in their lifetime. This risk varies dramatically by setting:
- Very high HDI countries: 27.6% (1 in 3.6)
- Low HDI countries: 12.0% (1 in 8.3)
This disparity reflects differences in life expectancy, diagnostic capacity, screening availability, and exposure to risk factors rather than inherent biological susceptibility.
2.2 Cancer Deaths (Mortality) in 2024
An estimated 9.7 million people died from cancer in 2024. Of all cancer deaths:
- Over 4.8 million occurred among adults aged 30–69 (premature mortality)
- Approximately 1 in 9 men and 1 in 13 women will die from cancer before age 75
2.3 Cancer as a Cause of Premature Death
In 2021 (WHO Global Health Estimates), cancer was:
- The leading cause of premature mortality (ages 30–69) in 41 countries
- The second leading cause in 37 countries
- The third leading cause in 47 countries
Cancer contributed approximately 16.5% of all global deaths (excluding COVID-19), making it the second leading cause of death worldwide after cardiovascular disease.
2.4 Disability-Adjusted Life Years (DALYs)
In 2021, cancer accounted for 9% of total global DALYs. This proportion increases substantially with age and income level:
| Age Group | Low-Income | Lower-Middle-Income | Upper-Middle-Income | High-Income | Global |
|---|---|---|---|---|---|
| <15 years | 0.72% | 0.82% | 2.84% | 2.62% | 1.08% |
| 15–29 years | 3.11% | 2.60% | 3.71% | 2.26% | 2.93% |
| 30–49 years | 7.75% | 6.83% | 10.16% | 7.15% | 8.10% |
| 50–69 years | 10.12% | 10.24% | 18.66% | 19.02% | 15.10% |
| ≥70 years | 6.64% | 5.95% | 12.96% | 16.82% | 11.98% |
Key trend: Between 2000 and 2021, the cancer share of DALYs increased from 1.2% to 1.4% in children <15 years, from 12.1% to 14.8% in ages 30–49, and from 22.8% to 27.3% in ages 50–69. This reflects both rising cancer incidence and successful communicable disease control in middle-aged populations.
3. Cancer by Continent, Income Level & Cancer Type
3.1 Geographic Distribution — Incidence (2024)
| Continent | New Cases | Share of Global Total |
|---|---|---|
| Asia | 10,347,487 | 53.1% |
| Europe | 4,084,307 | 20.9% |
| Northern America | 2,171,764 | 11.1% |
| Latin America & Caribbean | 1,497,228 | 7.7% |
| Africa | 1,187,697 | 6.1% |
| Oceania | 209,644 | 1.1% |
| TOTAL | 19,498,127 | 100% |
3.2 Geographic Distribution — Mortality (2024)
| Continent | Deaths | Share of Global Total |
|---|---|---|
| Asia | 5,492,805 | 56.6% |
| Europe | 1,942,955 | 20.0% |
| Latin America & Caribbean | 751,636 | 7.7% |
| Northern America | 718,602 | 7.4% |
| Africa | 721,629 | 7.4% |
| Oceania | 76,159 | 0.78% |
| TOTAL | 9,703,786 | 100% |
3.3 Cancer Cases by Income Level (2024)
| Income Category | New Cases (millions) |
|---|---|
| High-income countries (HICs) | 6.9 |
| Upper-middle-income countries (U-MICs) | 7.9 |
| Lower-middle-income countries (L-MICs) | 4.0 |
| Low-income countries (LICs) | 0.6 |
3.4 Age-Standardized Incidence Rates (ASIR) per 100,000 Population (2024)
| Income Category | ASIR (per 100,000) |
|---|---|
| High-income | 275 |
| Upper-middle-income | 197 |
| Low-income | 122 |
| Lower-middle-income | 119 |
3.5 Age-Standardized Mortality Rates (ASMR) per 100,000 Population (2024)
| Income Category | ASMR (per 100,000) |
|---|---|
| Upper-middle-income | 91 |
| High-income | 89 |
| Low-income | 79 |
| Lower-middle-income | 72.5 |
3.6 Top 10 Cancers by Type — Incidence (2024)
Men (9,933,770 total new cases):
| Rank | Cancer Type | Cases | % of Male Total |
|---|---|---|---|
| 1 | Lung (tracheal/bronchial/lung) | 1,632,033 | 16.4% |
| 2 | Prostate | 1,546,112 | 15.6% |
| 3 | Colorectal | 1,138,656 | 11.5% |
| 4 | Stomach | 638,780 | 6.4% |
| 5 | Liver | 586,676 | 5.9% |
| — | All other cancers | 4,391,513 | 44.2% |
Women (9,564,357 total new cases):
| Rank | Cancer Type | Cases | % of Female Total |
|---|---|---|---|
| 1 | Breast | 2,434,087 | 25.4% |
| 2 | Lung (tracheal/bronchial/lung) | 1,004,972 | 10.5% |
| 3 | Colorectal | 902,351 | 9.4% |
| 4 | Cervix uteri | 604,196 | 6.3% |
| 5 | Thyroid | 713,180 | 7.5% |
| — | All other cancers | 3,905,571 | 40.8% |
3.7 Top 10 Cancers by Type — Mortality (2024)
Men (5,448,245 total deaths):
| Rank | Cancer Type | Deaths | % of Male Total |
|---|---|---|---|
| 1 | Lung | 1,259,331 | 23.1% |
| 2 | Colorectal | 504,807 | 9.3% |
| 3 | Liver | 504,643 | 9.3% |
| 4 | Stomach | 418,996 | 7.7% |
| 5 | Pancreas | 232,106 | 4.3% |
| — | All other cancers | 2,528,362 | 46.4% |
Women (4,255,541 total deaths):
| Rank | Cancer Type | Deaths | % of Female Total |
|---|---|---|---|
| 1 | Breast | 693,660 | 16.3% |
| 2 | Lung | 602,508 | 14.2% |
| 3 | Colorectal | 413,088 | 9.7% |
| 4 | Cervix uteri | 279,583 | 6.6% |
| 5 | Ovary | ~232,000 | ~5.5% |
| — | All other cancers | 2,034,702 | 47.8% |
3.8 Childhood Cancer
An estimated 400,000 new cancers arise annually among children and adolescents (0–19 years old), with approximately 90% occurring in LMICs.
4. Future Projections — 2024 to 2050
4.1 Projected Global Cancer Incidence — 2024 to 2050
IARC estimates project a 66.7% global increase in cancer incidence by 2050, with new annual cases reaching 35 million (from 20.6 million in 2024).
By Income Level:
| Income Level | 2024 (millions) | 2050 (millions) | Increase |
|---|---|---|---|
| Low-income (LICs) | 0.58 | 1.36 | +133.3% |
| Lower-middle-income | 4.03 | 7.53 | +86.5% |
| Upper-middle-income | 8.13 | 12.2 | +50.5% |
| High-income | 7.18 | 10.6 | +46.9% |
By WHO Region:
| WHO Region | 2024 (millions) | 2050 (millions) | Increase |
|---|---|---|---|
| African Region | 0.96 | 2.16 | +125.2% |
| Eastern Mediterranean Region | 0.80 | 1.69 | +109.8% |
| South-East Asia Region | 4.34 | 7.13 | +64.3% |
| Western Pacific Region | 7.81 | 10.1 | +29.0% |
| European Region | 4.73 | 6.02 | +27.4% |
| Region of the Americas | 2.62 | 4.62 | +76.6% |
4.2 Drivers of the Increasing Burden
Three primary forces are driving the projected rise in cancer cases:
| Driver | Description | Impact |
|---|---|---|
| Population growth | Expanding populations add more people at risk | Significant |
| Ageing populations | Individuals aged 65+ accounted for 53% of all 2024 cancer cases | Most significant driver |
| Rising risk factor exposure | Increasing tobacco, alcohol, obesity, and unhealthy diets globally | Significant and growing |
4.3 Early-Onset Cancer in Young Adults
Between 1990 and 2019, global incidence of early-onset cancer (adults under 50) rose by 79.1%. People younger than 50 are the only age group to experience a sustained increase in cancer incidence from 1995 through 2021.
This trend is particularly notable for:
- Colorectal cancer: 83% of 63 monitored countries showed increasing incidence in ages 40–44; 92% in ages 45–49
- Breast cancer: Rising in most countries across most age groups
- Thyroid cancer: Rising in nearly all countries (linked partly to overdiagnosis from screening)
4.4 SDG 3.4 Progress: Premature Cancer Mortality
The SDG 3.4 target aims for a one-third reduction in premature mortality from NCDs (including cancer) by 2030.
| Progress Category | Number of Countries |
|---|---|
| On track to meet target | 12 |
| Rising rates of premature cancer mortality | 48 |
| Declining premature mortality rates (2000–2019) | 138 out of 183 (75%) |
5. Modifiable Risk Factors & Prevention
5.1 Overview: What Is Preventable
In 2022, 38% of all new cancer cases worldwide (7.0 million cases) were attributable to 30 modifiable risk factors:
- Men: 45% of incident cancers preventable (4.3 million cases)
- Women: 30% of incident cancers preventable (2.7 million cases)
The proportion of preventable cancers varied by region:
- Women: Ranged from 25% (Northern Africa & Western Asia) to 38% (sub-Saharan Africa)
- Men: Ranged from 28% (Latin America & Caribbean) to 57% (East Asia)
5.2 Top Controllable Risk Factors
| Rank | Risk Factor | % of All New Cancer Cases (2022) | Cases (2022) |
|---|---|---|---|
| 1 | Tobacco use | 15% | ~1.43 million |
| 2 | Infections (HPV, HBV, H. pylori, HCV, EBV) | 10% | ~2.3 million |
| 3 | Alcohol consumption | 3% | ~700,000 |
| 4 | Excess body weight (obesity) | 2.4% | 537,702 |
5.3 Tobacco Control
Current prevalence (2024):
- Global tobacco use prevalence: 19.5% of people aged 15+ (approximately 1.2 billion people)
- Male prevalence: 32.5%
- Female prevalence: 6.6%
- Regional variation: WHO European Region highest (24.1%); WHO African Region lowest (9.5%)
Progress achieved:
- 27% reduction in global tobacco use by 2025 vs. 2010 baseline (just short of the 30% SDG target)
- 155 countries have at least one best-practice MPOWER measure (up from 44 in 2007)
- 6.1 billion people covered by at least one best-practice MPOWER measure
- Mean MPOWER score approaching 34 (out of 100) globally
WHO Best Buys Implementation (2023):
| WHO Best Buy Intervention | LICs | L-MICs | U-MICs | HICs |
|---|---|---|---|---|
| National NCD targets | 46% | 70% | 79% | 53% |
| Mortality data available | 0% | 33% | 77% | 95% |
| Risk-factor surveys conducted | 62% | 76% | 87% | 90% |
| National NCD action plan | 50% | 65% | 65% | 69% |
| Tobacco taxes (best practice) | 27% | 37% | 60% | 83% |
| Smoke-free public places | 54% | 74% | 79% | 73% |
| Graphic health warnings | 58% | 81% | 75% | 90% |
| Complete tobacco advertising bans | 65% | 89% | 73% | 81% |
| Tobacco mass media campaigns | 12% | 44% | 42% | 56% |
5.4 Alcohol Control
- Global per-capita alcohol consumption: 5.0 liters in 2022 (down from 5.7 liters in 2010)
- In 2022, ~700,000 new cancer cases (3% of all cancers) were attributable to alcohol
- Alcohol consumption is projected to increase globally, led by South-East Asia and Western Pacific regions
- Only 16 of 46 sub-Saharan African countries have formal alcohol control policies
- SAFER policy implementation remains highly uneven, especially in LMICs
5.5 Obesity & Excess Body Weight
- In 2022, 537,702 new cancer cases were attributable to excess body weight (2.4% of total)
- Adult overweight prevalence ranges from ~31% (South-East Asia, Africa) to ~67% (Region of the Americas)
- No country has successfully halted the rise in obesity
- Projections depict dramatic increases in all WHO regions by 2050
- Obesity is rising faster in LMICs and small island developing states than in wealthier economies
5.6 Infection-Associated Cancers
- In 2022, 2.3 million new cancer cases (10% of all cancers) were attributable to infectious agents
- Key pathogens: H. pylori, HPV, hepatitis B virus (HBV), hepatitis C virus (HCV), and Epstein-Barr virus (EBV)
- Infection-related cancers decreased from 16% of all cancers in 2008 to 10% in 2022
- Progress driven by: HPV vaccination, HBV birth-dose vaccination (now in 115 countries), and HIV treatment
HPV Vaccination Progress:
- 85% of countries have integrated HPV vaccination into national immunization programs
- One-dose HPV vaccination schedule adopted by 91 countries (56% of all HPV vaccination programs)
- Global first-dose HPV coverage among girls: 31% (2026) — up from 17% in 2019
- WHO elimination target: 90% coverage by 2030
5.7 Physical Inactivity
- 31% of adults worldwide do not meet guideline recommendations for physical activity
- 80% of adolescents are insufficiently active
- Fewer than half of all countries have a current, costed, and funded national physical activity policy
6. Early Detection & Screening Programs
6.1 Early Diagnosis
Early-stage cancer diagnosis dramatically improves survival outcomes. Yet the gap between HICs and LMICs is stark:
| Metric | HICs | LMICs |
|---|---|---|
| Breast cancer diagnosed at Stage I + II | 91% | 28% |
NCCP Coverage of Early Detection:
- 90% of NCCPs include early detection for breast and cervical cancer
- Few have structured pathways with measurable targets
- Only 44% of NCCPs address diagnosis/staging with defined strategies and measurable indicators
6.2 Cancer Screening Programs
| Indicator | Status |
|---|---|
| Countries with national cancer screening programs | >75% |
| Countries with adopted HPV-based cervical screening | 45% |
| Cervical cancer 5-year screening coverage — LMICs | 26% (population-weighted, 2023) |
| Cervical cancer 5-year screening coverage — HICs | 74% (population-weighted, 2023) |
6.3 Breast Cancer Screening
- 45 countries report no breast cancer screening program at all
- 5 countries (Libya, Maldives, Republic of Moldova, Uzbekistan, Viet Nam) report only pilot programs
6.4 Breast Cancer Survival Inequity
New WHO survival estimates (2017–2021) reveal a four-fold difference in 5-year net survival between HICs and sub-Saharan African countries:
- Median age-standardized 5-year net survival in sub-Saharan Africa: 39%
- More than half of sub-Saharan African countries did not reach 50% survival
- Breast cancer 5-year survival in HICs often exceeds 85–90%
6.5 Childhood Cancer Survival
For acute lymphoid leukaemia (GICC target: 60% 5-year survival):
- 104 of 194 countries (54%) reached the 60% survival target for 2017–2021
- Sub-Saharan Africa: 19–74% survival (high country-level variation)
- European Region: 51–93% survival
- Region of the Americas: 22–92% survival
- CONCORD-4 (2015–2019): Survival >80% in most HICs; 60–80% in most U-MICs; 50–60% in participating L-MICs
7. Treatment Access — Surgery, Radiotherapy & Cancer Medicines
7.1 Cancer Surgery
- Growing existence of national surgical, obstetric and anaesthesia plans (NSOAPs) in >40 countries
- Limited inclusion in public-sector health benefit packages
- Post-operative mortality gap: 4–5× higher in LMICs vs. HICs (multi-country study)
7.2 Radiotherapy
| Indicator | Data |
|---|---|
| NCCPs with explicit radiotherapy strategies | ~50% |
| LMICs with populations >1 million and no radiation facility | 23 countries |
| LICs with radiotherapy reimbursement in national benefit packages | 19–25% |
| Countries with increased radiotherapy density per cancer patient (2020→2026) | 109 countries |
| Countries with decreased radiotherapy density (2020→2026) | 41 countries |
| Countries with no change in radiotherapy density (2020→2026) | 37 countries |
7.3 Systemic Therapy & Cancer Medicines
| Indicator | Data |
|---|---|
| Anti-cancer medicines analyzed by WHO EML | 50 |
| Median medicines appearing in national essential medicines lists (NEMLs) | 28 |
| Hospital availability in LICs and L-MICs | 9–54% |
| Hospital availability in HICs | 68–94% |
Cancer medicines expenditure has grown dramatically: in select HICs, cancer medicines increased from <10% of direct cancer expenditure in 1995 to >40% in 2023.
7.4 UHC Benefit Package Coverage
Only 28% of countries include a minimum cancer management package in their universal health coverage (UHC) benefit packages.
7.5 Impact of Out-of-Pocket Costs
In LMICs:
- High out-of-pocket costs cause catastrophic financial hardship
- Up to 90% of people unable to appropriately complete treatment in some settings
- Cancer is a leading driver of medical bankruptcy at household level
8. Financial & Human Cost: The Lived Experience
8.1 The WHO Global Lived Experience Survey
For the first time, WHO conducted a global cross-sectional survey on the lived experience of people affected by cancer (2024–2025):
- 4,262 total respondents; 3,975 provided complete responses
- Respondents across 116 countries (47% from LMICs)
- 1,505 individuals diagnosed with cancer themselves
- 2,470 reporting on experience of a family member/loved one
- Median age of people living with/beyond cancer: 49 years at survey; 43 years at diagnosis
- Survey available in 10 languages
8.2 Physical Quality of Life
| Symptom | % of Patients Reporting |
|---|---|
| Mild to severe pain | 55% (n=827/1,505) |
| Mild to very severe fatigue | 69% (n=1,038/1,505) |
8.3 Psychological & Mental Health
| Condition | Patients | Family Members/Caregivers |
|---|---|---|
| Depression | 25% | 20% |
| Anxiety | 22% | 17.8% |
| Post-traumatic stress disorder (PTSD) | 10.6% | 11.3% |
| Estimated % experiencing mental illness | ~60% | — |
| Report discrimination or social stigma | Significant | — |
| Grief (living with/beyond cancer) | 24.5% | 21% |
8.4 Caregiving Burden
- About 30% of family members (n=729/2,470) reported one or more forms of caregiving strain
- Of 2,470 family member respondents, 163 reported unemployment due to health reasons
- Of those, 54% (88) reported unemployment was due to caregiving requirements
8.5 Education & Employment Impact
| Outcome | % Affected |
|---|---|
| People with cancer experiencing unemployment | 11.4% (n=454/3,975) |
| Experiencing job loss or reduced work hours | 16% (n=636/3,975) |
| Experiencing education disruption (reduced hours or discontinued studies) | 5% (n=198/3,975) |
| Cancer patients returning to work | <47% |
| Experiencing job loss post-diagnosis | 9% overall; 35% for advanced cancer |
| Becoming unemployed | 29% |
| Retiring early | 14% |
| Receiving long-term disability benefits | 11% |
| Average caregiver providing unpaid support | >50 days |
| Average caregiver unpaid hours per week | ~45 hours |
| Employed caregivers reducing work hours | 13% reduction on average |
| Caregivers experiencing presenteeism | 24% reduction in workplace productivity |
8.6 Social Relationships
- Of 3,191 respondents in a relationship at time of cancer experience:
- 9% reported their relationship was challenged
- 20% reported relationship stayed the same or grew stronger
- Approximately 50% of caregivers (n=527/1,010) reported strained friendships with friends and extended family
8.7 Financial Toxicity
| Finding | Data |
|---|---|
| Patients and families experiencing catastrophic health expenditure | ~45–60% |
| Cancer as a driver of household medical bankruptcy | Leading cause globally |
| Return on investment in cancer prevention & control | US$ 9.50 per $1 invested |
8.8 The Intergenerational Impact: Children Orphaned by Cancer
In 2020:
- 4.4 million cancer deaths among women; 5.5 million among men
- 1.04 million children became maternal orphans due to cancer (women dying of cancer)
- 1.41 million children became paternal orphans due to cancer (men dying of cancer)
- Of 1 million new maternal orphans:
- 1 in 4 lost their mother to breast cancer
- 1 in 5 lost their mother to cervical cancer
- Almost half were in Asia; more than one-third in Africa
- Six countries accounted for two-fifths of worldwide maternal orphans: India, China, Nigeria, Indonesia, Ethiopia, and Pakistan
8.9 The Universal Reach of Cancer
When factoring in impacts on family members and caregivers, approximately 92% of all people globally will be affected by cancer at least once in their lifetime — either through personal diagnosis or as a caregiver of a parent, spouse, child, or close family member.
In HICs, individuals can expect to be affected by cancer twice during their lifetime: once as a patient and once as a caregiver.
9. Policy Progress & Implementation Gaps
9.1 National Cancer Control Plans (NCCPs)
| Indicator | 2010 | 2021 | Change |
|---|---|---|---|
| Countries with dedicated NCCPs | 50% | 82% | +32 pp |
| Countries with cancer guidelines | — | 73% | — |
| Guidelines utilized in ≥50% of facilities | — | 52% | — |
| Countries including comprehensive cancer in UHC benefit package | — | 28% | — |
9.2 WHO Best Buys Implementation — Full Status Table
| WHO Best Buys Intervention | Global Average | LIC | L-MIC | U-MIC | HIC |
|---|---|---|---|---|---|
| National NCD targets | 64% | 46% | 70% | 79% | 53% |
| Mortality data available | 60% | 0% | 33% | 77% | 95% |
| Risk-factor surveys conducted | 80% | 62% | 76% | 87% | 90% |
| National NCD action plan | 63% | 50% | 65% | 65% | 69% |
| Tobacco taxes (best practice) | 56% | 27% | 37% | 60% | 83% |
| Smoke-free public places | 73% | 54% | 74% | 79% | 73% |
| Graphic health warnings | 79% | 58% | 81% | 75% | 90% |
| Complete tobacco advertising bans | 79% | 65% | 89% | 73% | 81% |
| Tobacco mass media campaigns | 42% | 12% | 44% | 42% | 56% |
| Alcohol-sale restrictions | ~85% | 88% | 81% | 92% | 90% |
9.3 Palliative Care
| Indicator | Data |
|---|---|
| People needing palliative care annually | 73 million |
| People who actually receive palliative care | ~14% (approximately 10 million) |
| NCCPs including palliative care | 69% of governments dedicate funding |
| Survivorship strategies in NCCPs | 52% include post-treatment follow-up strategies |
| LMICs with access to rehabilitation services | <50% |
| LMICs with oncofertility pathways | ~20% |
9.4 The Implementation Paradox
Despite significant progress in cancer policy adoption:
- Only 28% of countries include comprehensive cancer in UHC benefit packages
- Catastrophic health expenditure prevalence from cancer: approximately 50–60% globally
- Only 30% of NCCPs incorporate cancer prevention interventions
- Workforce gaps of 2–5× between HICs and LMICs persist
10. The Three Shifts: Better Capabilities, Protections & Value
WHO’s report calls for a fundamental reorientation of the global cancer agenda through three shifts, coordinated around seven recommendations targeting governments, international organizations, civil society, academic institutions, the private sector, and WHO.
Shift 1: Better Capabilities
Goal: Strengthen the health system infrastructure and workforce to deliver comprehensive, integrated cancer services for all.
This means:
- Embedding cancer control within UHC and health system strengthening
- Using NCCPs as the catalyst for strategic, funded action
- Building workforce capacity across the cancer care continuum
- Expanding access to radiotherapy, surgery, and essential cancer medicines
- Integrating cancer data into health information systems
Shift 2: Better Protections
Goal: Protect people from the human, financial, and social consequences of cancer through social protection and equity-centered policies.
This means:
- Including people with lived experience in all cancer-related decision-making
- Enhancing community-level health promotion and cancer literacy
- Strengthening social protection systems for cancer patients and caregivers
- Addressing inequities across gender, race, geography, disability, and socioeconomic status
- Protecting children orphaned by cancer through targeted social support
Shift 3: Better Value
Goal: Ensure that investments, research, and innovation deliver maximum value — measured in survival, function, and quality of life — rather than in technological sophistication alone.
This means:
- Aligning research and innovation with public health priorities and LMIC service needs
- Promoting transparency and global alignment in cancer data
- Adopting value-based care frameworks that prioritize clinical benefit over commercial returns
- Unifying the cancer agenda around equity-based, system-wide solutions
- Establishing population-based cancer registries as the foundation for accountability
11. Seven WHO Recommendations
Recommendation 1: Embed Cancer Control Within Health System Strengthening & UHC
Governments should use NCCPs as the catalyst for strategic, funded, and integrated action that embeds cancer services within UHC.
Recommendation 2: Strengthen Health System Capacities for Comprehensive, Integrated Cancer Service Delivery
Governments should build capacity for early detection, diagnosis, treatment, and survivorship care across all income settings.
Recommendation 3: Include People with Lived Experience in All Cancer-Related Decision-Making
All stakeholders should meaningfully engage patients, caregivers, and survivors as partners in policy design, implementation, and evaluation.
Recommendation 4: Enhance Community-Level Health Promotion on Cancer & Strengthen Social Protections
Governments and civil society should strengthen health literacy, address stigma, and provide financial and social protections for affected families.
Recommendation 5: Promote Alignment & Transparency in Global Cancer Data on Burden & Health System Performance
WHO, IARC, and Member States should strengthen population-based cancer registries and use the WHO Global Cancer Monitoring Framework for systematic, globally aligned progress tracking.
Recommendation 6: Unify the Cancer Agenda Around Equity-Based, System-Wide Solutions
All stakeholders should address the structural, commercial, and political determinants of inequity in cancer outcomes.
Recommendation 7: Align Research & Innovation with Public Health Priorities & LMIC Needs
Funders, researchers, and the private sector should ensure that innovation serves equity — prioritizing interventions that deliver the greatest clinical benefit at the greatest access.
12. Complete Data Tables Compilation
Table A: Global Cancer Statistics at a Glance (2024)
| Metric | Value | Notes |
|---|---|---|
| New cancer cases (incl. NMSC) | 20.6 million | — |
| New cancer cases (excl. NMSC) | 19.5 million | 9.9M male, 9.6M female |
| Cancer deaths | 9.9 million | — |
| New childhood cancers (ages 0–19) | ~400,000/year | ~90% in LMICs |
| Cumulative risk of developing cancer (0–74) | 19.8% | ~1 in 5 |
| Lifetime risk of being affected by cancer | ~92% | Personal or as caregiver |
| Leading cause of premature death (countries) | 41 | 2021 WHO GHE |
| Cases projected by 2050 | 35 million/year | +66.7% from 2024 |
| Preventable through modifiable risk factors | ~38% | 2022 data |
| Economic cost 2020–2050 | US$ 33.2 trillion | Annual GDP tax: 0.55% |
| ROI in cancer prevention & control | US$ 9.50 per $1 invested | Social return |
Table B: Top 5 Cancers — Incidence & Mortality by Sex (2024)
| Rank | Men — Cancer | Male Cases | Male Deaths | Women — Cancer | Female Cases | Female Deaths |
|---|---|---|---|---|---|---|
| 1 | Lung | 1,632,033 | 1,259,331 | Breast | 2,434,087 | 693,660 |
| 2 | Prostate | 1,546,112 | 419,849 | Lung | 1,004,972 | 602,508 |
| 3 | Colorectal | 1,138,656 | 504,807 | Colorectal | 902,351 | 413,088 |
| 4 | Stomach | 638,780 | 418,996 | Cervix uteri | 604,196 | 279,583 |
| 5 | Liver | 586,676 | 504,643 | Thyroid | 713,180 | ~232,000 |
Table C: Geographic Distribution of Cancer Burden (2024)
| Continent | Incidence (Cases) | % | Mortality (Deaths) | % |
|---|---|---|---|---|
| Asia | 10,347,487 | 53.1% | 5,492,805 | 56.6% |
| Europe | 4,084,307 | 20.9% | 1,942,955 | 20.0% |
| Northern America | 2,171,764 | 11.1% | 718,602 | 7.4% |
| Latin America & Caribbean | 1,497,228 | 7.7% | 751,636 | 7.7% |
| Africa | 1,187,697 | 6.1% | 721,629 | 7.4% |
| Oceania | 209,644 | 1.1% | 76,159 | 0.8% |
Table D: Cancer Incidence by Income Level (2024)
| Income Category | Cases (millions) | ASIR per 100,000 | ASMR per 100,000 |
|---|---|---|---|
| High-income | 6.9 | 275 | 89 |
| Upper-middle-income | 7.9 | 197 | 91 |
| Lower-middle-income | 4.0 | 119 | 72.5 |
| Low-income | 0.6 | 122 | 79 |
Table E: Projected Cancer Incidence Growth — 2024 to 2050
| Category | 2024 (M) | 2050 (M) | % Increase |
|---|---|---|---|
| Global Total | 19.5 | 35.0 | +66.7% |
| Low-income countries | 0.58 | 1.36 | +133.3% |
| Lower-middle-income | 4.03 | 7.53 | +86.5% |
| Region of the Americas | 2.62 | 4.62 | +76.6% |
| Upper-middle-income | 8.13 | 12.2 | +50.5% |
| High-income | 7.18 | 10.6 | +46.9% |
| Western Pacific | 7.81 | 10.1 | +29.0% |
| European Region | 4.73 | 6.02 | +27.4% |
| South-East Asia | 4.34 | 7.13 | +64.3% |
| Eastern Mediterranean | 0.80 | 1.69 | +109.8% |
| African Region | 0.96 | 2.16 | +125.2% |
Table F: Modifiable Risk Factors — Cancer Attributable Cases (2022)
| Risk Factor | % of All Cases | Estimated Cases | Trend |
|---|---|---|---|
| Tobacco use | 15% | ~1.43 million | ↓ Declining (27% reduction since 2010) |
| Infections (HPV, HBV, etc.) | 10% | ~2.3 million | ↓ Improving (16%→10% since 2008) |
| Alcohol | 3% | ~700,000 | ↑ Rising projected |
| Obesity/excess weight | 2.4% | 537,702 | ↑ Worsening (no country halted rise) |
| All combined | 38% | ~7.0 million | — |
Table G: Tobacco Control Progress (2024)
| Indicator | Value |
|---|---|
| Global tobacco prevalence (age 15+) | 19.5% (~1.2 billion users) |
| Male prevalence | 32.5% |
| Female prevalence | 6.6% |
| Reduction since 2010 baseline | 27% (near 30% target) |
| Countries with ≥1 MPOWER measure | 155 (up from 44 in 2007) |
| People covered by best-practice MPOWER | 6.1 billion |
| Countries achieving best-practice tobacco taxes | 56% overall; 83% HICs; 27% LICs |
Table H: HPV & Cervical Cancer Elimination Progress
| Indicator | Current Status | WHO 2030 Target |
|---|---|---|
| Countries with HPV in national immunization | 85% | 100% |
| Countries adopting one-dose HPV schedule | 91 (56% of programs) | — |
| Global HPV first-dose coverage (girls) | 31% (2026, up from 17% in 2019) | 90% |
| Cervical cancer 5-year screening — LMICs | 26% | — |
| Cervical cancer 5-year screening — HICs | 74% | — |
| Cervical cancer deaths in 2024 (women) | 279,583 | Elimination target |
Table I: Treatment Access & UHC Gaps
| Domain | Key Statistic |
|---|---|
| Countries with cancer in UHC benefit package | 28% |
| LMIC breast cancer diagnosed at early stage (I+II) | 28% vs. 91% in HICs |
| Countries with no breast cancer screening program | 45 |
| LMICs with no radiotherapy facility (pop. >1M) | 23 countries |
| LICs with radiotherapy in national benefit package | 19–25% |
| Cancer medicines appearing in NEMLs (median) | 28 of 50 analyzed |
| Hospital availability of cancer medicines — HICs | 68–94% |
| Hospital availability of cancer medicines — LICs/L-MICs | 9–54% |
| Post-operative mortality gap (LMIC vs. HIC) | 4–5× higher |
Table J: Lived Experience Survey — Key Findings
| Domain | Finding |
|---|---|
| Survey respondents | 4,262 (3,975 complete); 116 countries; 47% LMICs |
| Patients vs. family member respondents | 1,505 patients; 2,470 family members |
| Patients reporting pain | 55% |
| Patients reporting fatigue | 69% |
| People with cancer experiencing mental illness | ~60% |
| Depression — patients vs. caregivers | 25% vs. 20% |
| Anxiety — patients vs. caregivers | 22% vs. 17.8% |
| PTSD — patients vs. caregivers | 10.6% vs. 11.3% |
| Patients/families experiencing catastrophic spending | ~45–60% |
| Patients returning to work after treatment | <47% |
| Caregivers reporting relationship strain | ~50% |
| People needing palliative care annually | 73 million |
| People receiving palliative care | ~14% (~10 million) |
Table K: NCCP & Policy Implementation Status
| Indicator | 2010 | 2021 | Status |
|---|---|---|---|
| Countries with dedicated NCCPs | 50% | 82% | Significant progress |
| Countries with cancer guidelines | — | 73% | — |
| Guidelines used in ≥50% of facilities | — | 52% | — |
| Cancer included in UHC benefit package | — | 28% | Severe gap |
| NCCPs incorporating prevention interventions | — | 30% | Severe gap |
| Countries on track for SDG 3.4 | — | 12 | Critical shortfall |
| Countries with rising premature cancer mortality | — | 48 | Worsening trend |
13. SEO Keywords & Optimization
Primary Keywords
- WHO global cancer report 2026
- global cancer statistics 2024 2025 2026
- cancer incidence mortality by country 2024
- cancer prevention risk factors WHO 2026
- WHO cancer control recommendations 2026
- cancer survival rates by income level
- cervical cancer HPV vaccination coverage 2026
- tobacco control cancer prevention MPOWER
- cancer economic burden cost 2020-2050
- universal health coverage cancer treatment access
Secondary Keywords
- cancer burden Asia Europe Africa 2024
- breast cancer survival inequity HIC LIC
- childhood cancer incidence LMIC
- SDG 3.4 cancer premature mortality
- cancer palliative care access 2026
- lived experience cancer survey WHO
- national cancer control plan implementation
- radiotherapy access LMIC gap
- cancer financial toxicity bankruptcy
- children orphaned by cancer 2020
Long-Tail Keywords
- how many people diagnosed with cancer worldwide 2024 WHO statistics
- why is cancer mortality higher in low-income countries
- what percentage of cancers are preventable through lifestyle changes
- WHO recommendations for cancer prevention and control 2026
- HPV vaccination one-dose schedule effectiveness coverage
- cancer economic cost 33.2 trillion 2020-2050
- global cancer cases projected 35 million by 2050
- disparities in breast cancer survival between rich and poor countries
- 92% of people affected by cancer lifetime personal family caregiver
- SDG cancer target 2030 how many countries on track 2026
Article Metadata
- Target URL slug: who-global-cancer-report-2026-statistics
- Focus keyphrase: WHO global cancer report 2026
- Meta title: WHO Global Cancer Report 2026: 20.6M Cases, 9.7M Deaths & Full Data Tables
- Meta description: Complete analysis of the WHO Global Status Report on Cancer 2026. Covers 20.6M new cases, 35M projected by 2050, top cancer types by sex, geographic distribution, prevention data, HPV vaccination rates, treatment access gaps, and WHO’s seven recommendations.
- Category: Public Health | WHO Reports | Cancer Research | Global Health
- Reading time: ~40 minutes
- Word count: ~6,500+ words
- Data tables: 11 major tables + 30+ inline data sets
- Source: WHO/IARC, Global Status Report on Cancer 2026, CC BY-NC-SA 3.0 IGO
Key Conclusions
- The global cancer burden is growing but unequal. 20.6 million new cases and 9.7 million deaths in 2024 are projected to reach 35 million cases annually by 2050. The steepest rises will be in low-income countries (+133%) and sub-Saharan Africa (+125%), whose health systems are least equipped to respond.
- Most cancers are preventable. Nearly 40% of new cases are attributable to modifiable risk factors — tobacco (15%), infections (10%), alcohol (3%), and obesity (2.4%). Tobacco control has delivered a 27% reduction in use since 2010. HPV vaccination is accelerating, but global first-dose coverage remains at just 31% vs. the 90% WHO elimination target.
- Survival should not depend on your postcode. Breast cancer 5-year survival exceeds 85% in HICs but falls below 45% in LICs. Only 28% of LMICs diagnose most breast cancers at an early stage (vs. 91% in HICs). Treatment access gaps — radiotherapy absent in 23 LMICs, cancer medicines missing from national formularies — are costing lives.
- Cancer’s human cost reaches far beyond the patient. 92% of all people globally will be affected by cancer in their lifetime — personally or as caregivers. Approximately 60% of people with cancer experience mental illness; 45–60% face catastrophic health spending; fewer than 47% return to work after treatment. In 2020, cancer orphaned 2.45 million children.
- The economic case for investment is overwhelming. Cancer costs US$ 33.2 trillion from 2020–2050 (0.55% annual global GDP tax), yet every US$ 1 invested in prevention and control yields a social return of US$ 9.50.
- Progress is possible — and uneven. 155 countries now have tobacco control measures; 82% of countries have NCCPs; cervical cancer elimination is within reach. But only 12 countries are on track to meet the SDG premature mortality target, and 48 countries have rising premature death rates.
- The future is a choice. WHO’s 2026 report concludes with a clear message: the primary gap is no longer knowledge, but the gap between what we know and what we implement. The future of cancer control will be shaped by whether governments, health systems, researchers, and societies choose to invest in better capabilities, provide better protections, and pursue better value — for all people, everywhere.
